Fundraise / allotmentFiled on BSE ·

Orchid Pharma QIP: ₹400 Cr (13 Nov 2026)

Orchid Pharma Limited QIP proceeds utilization and monitoring report for Q2 FY 2026-27

Orchid Pharma · Pharmaceuticals & Biotechnology

Arthneeti Research DeskPublished 1 min read
₹400 CrFundraise / allotment

Key highlights

  • Rs. 400 crore QIP proceeds monitored by CARE Ratings Ltd, report dated Nov 11, 2026
  • Rs. 135 crore invested in Orchid Bio Pharma Ltd for Jammu facility; commercial operations expected Feb 2027
  • Rs. 195.46 crore used for repayment of borrowings; Rs. 0.36 crore utilized for new API block at Alathur; general corporate purpose fully utilized at Rs. 63.72 crore

Original filing

Announcement under Regulation 30 (LODR)-Monitoring Agency Report

Read the filing on BSE (PDF) →

Companies guiding to strong growth

Ranked by management's own guidance on revenue and margins — not by us.

Rossell Techsys

Aerospace & Defense

Revenue growth 40%+Margin up 2%+

Sign up free to see all 6 →

See full rankings

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

More from Orchid Pharma

Other fundraise / allotment filings this fortnight

All fundraise / allotment filings →

Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.